ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference

ibio-member-picture-sumant

ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference

LOS ANGELES, Calif., March 26, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 Cell and Gene Meeting on the Med, to be held from April 9-11, 2024 in Rome, Italy.

Sumant Ramachandra, M.D., Ph.D., ImmPACT Bio’s chief executive officer, will provide a company presentation on Tuesday, April 9, 2024 at 12:00 PM CET. Dr. Ramachandra will also participate in an individual presentation and panel discussion entitled, “Advances in Targeting Autoimmune Disease,” on Wednesday, April 10, 2024 at 10:45 AM CET.

Virtual attendance is available which includes a livestream of ImmPACT Bio’s presentation and the ability to view all conference sessions on-demand. Please visit https://meetingonthemed.com/ for full information including registration.

View a recording of the presentation: https://www.youtube.com/watch?v=uTqycWrEXkA

About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. The company’s logic-gate-based CAR T-cell platforms, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to deplete B cells, prevent antigen escape, and overcome the immunosuppressive tumor microenvironment. The company’s technology is based on the work of pioneering scientists Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA.  For more information, visit http://www.immpact-bio.com.

Contacts for inquiries or additional information:

For investors:
InvestorRelations@immpact-bio.com

Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com

For media:
Kathy Vincent
Greig Communications
kathy@greigcommunications.com

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

ImmPACT Bio is now part of Lyell Immunopharma

If you have a question about a clinical trial, please contact us at info@immpact-bio.com